Sodium-glucose cotransporter inhibitor/inhibition (SGLTi), initially approved as a glucose-
lowering therapy for type 2 diabetes, is associated with decreased risks for many of the most …

Background The effect of sodium–glucose cotransporter 2 (SGLT2) inhibitors on cancer has
yet to be fully elucidated. Objective This systematic review and meta-analysis investigated …

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2I) have been suggested to
reduce new-onset cancer amongst type-2 diabetes mellitus (T2DM) patients. This study aims …

Introduction Sodium glucose co-transporter 2-inhibitors (SGLT2-I), antihyperglycemic
agents, are increasingly prescribed in chronic heart failure (CHF). Their risk for drug–drug …

Diabetes mellitus (DM) is a significant risk factor for various cancers, with the impact of anti-
diabetic therapies on cancer progression differing across malignancies. Among these …

Background: GLOB-cAGE is a newly established unprecedented consortium that brings
together cohorts of older persons with cardiovascular disease worldwide. GLOB-cAGE aims …

Background: Type 2 diabetes mellitus (T2DM) may be a risk factor for development of
hepatocellular carcinoma (HCC). The association between risk of developing HCC and …

Methods We conducted a retrospective study using a Japanese medical claims database.
Among patients with T2DM who were prescribed SGLT2i or DPP4i (n= 1,628,656), patients …

Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT‐2is) have been demonstrated to be
associated with cancer cell mechanisms. However, whether they increase the risk of cancer …

Cancer and diabetes are significant diseases that pose a threat to human health. Their
interconnection is complex, particularly when they coexist, often necessitating multiple …